Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A WHO grade ll astrocytic tumor with a relatively favorable prognosis. It is characterized by pleomorphic and lipidized cells expressing GFAP often surrounded by a reticulin network and eosinophilic granular bodies. It presents in the superficial cerebral hemispheres and involves the meninges. It typically affects children and young adults.
Biomarker and diagnostic research for pleomorphic xanthoastrocytoma has been reported in the published literature.
6 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and procedural interventions. Pipeline includes 1 PHASE4, 2 PHASE2, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04541082](https://clinicaltrials.gov/study/NCT04541082) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:54 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
PHASE1 |
Jazz Pharmaceuticals |
RECRUITING |
[NCT03919071](https://clinicaltrials.gov/study/NCT03919071) | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | PHASE2 | National Cancer Institute (NCI) | UNKNOWN |
[NCT03975829](https://clinicaltrials.gov/study/NCT03975829) | Pediatric Long-Term Follow-up and Rollover Study | PHASE4 | Novartis Pharmaceuticals | ACTIVE_NOT_RECRUITING |
[NCT04065776](https://clinicaltrials.gov/study/NCT04065776) | Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma | NA | St. Jude Children's Research Hospital | UNKNOWN |
[NCT05180825](https://clinicaltrials.gov/study/NCT05180825) | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy | PHASE2 | University Hospital, Strasbourg, France | UNKNOWN |
74 publications have been identified in PubMed for pleomorphic xanthoastrocytoma. Research spans Case Report / Case Series (46%), Basic Science / Preclinical (19%), and Clinical Trial Publication (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 34 | 46% |
Laboratory research | 14 | 19% |
Clinical study results | 9 | 12% |
Research summaries | 7 | 9% |
Testing and diagnosis research | 5 | 7% |
Disease patterns and progression | 4 | 5% |
New treatment approaches | 1 | 1% |
Takayama Y (2026). [PMID: 41798681](https://pubmed.ncbi.nlm.nih.gov/41798681/). *Neuro-oncology advances*. [Epidemiology / Natural History]
Saliba T (2026). [PMID: 41340779](https://pubmed.ncbi.nlm.nih.gov/41340779/). *Radiology case reports*. [Case Report / Case Series]
Alturkustani MA (2026). [PMID: 42238831](https://pubmed.ncbi.nlm.nih.gov/42238831/). *Neurosciences (Riyadh)*. [Basic Science / Preclinical]
Haj Mohammad SF (2026). [PMID: 41830662](https://pubmed.ncbi.nlm.nih.gov/41830662/). *European journal of cancer (Oxford, England : 1990)*. [Clinical Trial Publication]
Oshima S (2026). [PMID: 42217076](https://pubmed.ncbi.nlm.nih.gov/42217076/). *Jpn J Radiol*. [Review / Meta-Analysis]
Jader A (2026). [PMID: 42114162](https://pubmed.ncbi.nlm.nih.gov/42114162/). *J Neurosurg Case Lessons*. [Case Report / Case Series]
D'Amico RS (2026). [PMID: 41847840](https://pubmed.ncbi.nlm.nih.gov/41847840/). *Cancer Rep (Hoboken)*. [Case Report / Case Series]
Das S (2026). [PMID: 41954087](https://pubmed.ncbi.nlm.nih.gov/41954087/). *Adv Anat Pathol*. [Basic Science / Preclinical]
Pelissier L (2026). [PMID: 41591436](https://pubmed.ncbi.nlm.nih.gov/41591436/). *Pediatr Radiol*. [Review / Meta-Analysis]
Qi P (2026). [PMID: 41568500](https://pubmed.ncbi.nlm.nih.gov/41568500/). *Current cancer drug targets*. [Basic Science / Preclinical]